BrainsWay (NASDAQ:BWAY) vs. United American Healthcare (OTCMKTS:UAHC) Critical Comparison

BrainsWay (NASDAQ:BWAY) and United American Healthcare (OTCMKTS:UAHC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.

Insider and Institutional Ownership

30.1% of BrainsWay shares are held by institutional investors. 19.0% of BrainsWay shares are held by company insiders. Comparatively, 14.3% of United American Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares BrainsWay and United American Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BrainsWay	3.88%	3.52%	2.26%
United American Healthcare	N/A	N/A	N/A

Valuation & Earnings

This table compares BrainsWay and United American Healthcare”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrainsWay	$38.63 million	5.21	-$4.20 million	$0.10	106.90
United American Healthcare	N/A	N/A	$720,000.00	N/A	N/A

United American Healthcare has lower revenue, but higher earnings than BrainsWay.

Risk and Volatility

BrainsWay has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, United American Healthcare has a beta of -1.29, meaning that its stock price is 229% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for BrainsWay and United American Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrainsWay	0	0	3	0	3.00
United American Healthcare	0	0	0	0	0.00

BrainsWay presently has a consensus target price of $13.17, suggesting a potential upside of 23.17%. Given BrainsWay’s stronger consensus rating and higher possible upside, research analysts clearly believe BrainsWay is more favorable than United American Healthcare.

Summary

BrainsWay beats United American Healthcare on 10 of the 11 factors compared between the two stocks.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

About United American Healthcare

United American Healthcare Corporation, through its subsidiaries, provides contract manufacturing services to the medical device industry. It also focuses on the production of natural rubber. The company was incorporated in 1983 and is based in Chicago, Illinois.